As new treatments, cutting edge research, and a better understanding of genetic sequencing and mutations bring innovative change to the treatment landscape for neuromusclar disease, understanding your options and accessing care is more important than ever. We sit down with Dr. Matthew Harms, a neuromuscular neurologist and neruogenetics expert, to discuss what these changes mean to our community as he shares his advice, insights, and expertise on the changing landscape of neuromuscular care.

Dr. Matthew Harms is a neuromuscular neurologist and neurogenetics expert focused on ALS and related motor neuron diseases.  Dr. Harms' lab applies cutting-edge genetic sequencing technologies to discover new genes, define the frequency and range of genetic mutations in ALS, and characterize links between specific mutations and specific types or manifestations of ALS.  He is the Director of Precision Medicine Initiatives at Columbia University, Director of the Neurogenetics Program in the Department of Neurology, and Associate Director of the Eleanor and Lou Gehrig ALS Center.  Dr. Harms also serves as a Medical Advisor to the MDA.

Mindy Henderson is the Editor-in-Chief of MDA's Quest family of content and the host of this podcast.  She was diagnosed with Spinal Muscular Atrophy, type 2 when she was 15 months old and has been a life-long partner to MDA.  Mindy is also a motivational speaker and a writer, with her first book set to hit book stores in Summer of 2022.

Connect with Mindy:

LinkedIn: https://www.linkedin.com/in/hendersonmindy/

Instagram: https://www.instagram.com/mindyhendersonspeaks/